256 related articles for article (PubMed ID: 26595367)
1. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
[TBL] [Abstract][Full Text] [Related]
2. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
3. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
4. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
5. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.
Argilés JM; Figueras M; Ametller E; Fuster G; Olivan M; de Oliveira CC; López-Soriano FJ; Isfort RJ; Busquets S
Muscle Nerve; 2008 Feb; 37(2):190-5. PubMed ID: 17912749
[TBL] [Abstract][Full Text] [Related]
6. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
8. Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.
Kenley RA; Denissenko MF; Mullin RJ; Story J; Ekblom J
Oncol Rep; 2008 May; 19(5):1113-21. PubMed ID: 18425366
[TBL] [Abstract][Full Text] [Related]
9. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
10. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
11. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Hatakeyama S; Summermatter S; Jourdain M; Melly S; Minetti GC; Lach-Trifilieff E
Skelet Muscle; 2016; 6():26. PubMed ID: 27462398
[TBL] [Abstract][Full Text] [Related]
12. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
13. Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice.
Moore-Carrasco R; Figueras M; Ametller E; López-Soriano FJ; Argilés JM; Busquets S
Oncol Rep; 2008 Jan; 19(1):253-6. PubMed ID: 18097603
[TBL] [Abstract][Full Text] [Related]
14. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
15. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo.
Béchir N; Pecchi É; Relizani K; Vilmen C; Le Fur Y; Bernard M; Amthor H; Bendahan D; Giannesini B
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E539-49. PubMed ID: 26837807
[TBL] [Abstract][Full Text] [Related]
17. β
Scholpa NE; Simmons EC; Tilley DG; Schnellmann RG
Exp Neurol; 2019 Dec; 322():113064. PubMed ID: 31525347
[TBL] [Abstract][Full Text] [Related]
18. Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.
Gómez-SanMiguel AB; Gomez-Moreira C; Nieto-Bona MP; Fernández-Galaz C; Villanúa MÁ; Martín AI; López-Calderón A
Am J Physiol Endocrinol Metab; 2016 Jun; 310(11):E925-37. PubMed ID: 27245339
[TBL] [Abstract][Full Text] [Related]
19. Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.
Quanjun Y; Genjin Y; Lili W; Bin L; Jin L; Qi Y; Yan L; Yonglong H; Cheng G; Junping Z
Mol Biosyst; 2013 Dec; 9(12):3015-25. PubMed ID: 24056883
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction.
Pistilli EE; Bogdanovich S; Mosqueira M; Lachey J; Seehra J; Khurana TS
Am J Physiol Regul Integr Comp Physiol; 2010 Jan; 298(1):R96-R103. PubMed ID: 19864340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
